Ulises Bonillaburgos, MD
Family Practice · Mercedes, TXNPI 1750715868
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Boehringer Ingelheim at 33.0% of the total. Reporting peaked in 2019 at $630 and has fallen 90.8% since, to $58 in 2021. Among family practice clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 54 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$298
- AstraZeneca$183
- Novo Nordisk$154
- Astellas Pharma US Inc$132
- Pfizer$45
- Lilly USA, LLC$33
- plus $58 from 3 others
What the payments were for
- Food & beverage$904100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 16 | $298 |
| AstraZeneca | 10 | $183 |
| Novo Nordisk | 12 | $154 |
| Astellas Pharma US Inc | 8 | $132 |
| Pfizer | 3 | $45 |
| Lilly USA, LLC | 2 | $33 |
| Radius Health, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
How this compares
$904 in reported general payments places this provider in the 95th percentile of 646 family practice providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 142 | $202,206 |
| OzempicSemaglutide | 94 | $134,779 |
| TradjentaLinagliptin | 118 | $134,209 |
| JanuviaSitagliptin Phosphate | 116 | $131,515 |
| TrulicityDulaglutide | 57 | $126,684 |
| EliquisApixaban | 37 | $53,837 |
| RybelsusSemaglutide | 29 | $52,071 |
| LinzessLinaclotide | 64 | $51,699 |
| MounjaroTirzepatide | 30 | $49,652 |
| FarxigaDapagliflozin Propanediol | 34 | $48,520 |
| JanumetSitagliptin Phos/Metformin Hcl | 29 | $42,547 |
| MyrbetriqMirabegron | 37 | $35,164 |
| XareltoRivaroxaban | 22 | $27,490 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $22,859 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $21,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto, Synjardy | $298 | $390,898308 claims |
| Novo NordiskOzempic, Rybelsus | $154 | $186,850123 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $33 | $176,33687 claims |
| PfizerEliquis | $45 | $53,83737 claims |
| AstraZenecaFarxiga | $183 | $48,52034 claims |
| Astellas Pharma US IncMyrbetriq | $132 | $35,16437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 646 family practice providers in Texas.
Other family practice in Mercedes
- Mark RobbinsSchertz$99K
- Lena BruceSanta Fe$8K
- Akhila ReddyHouston$7K
- William CalleyGarland$7K
- Leticia Arredondo CerdaSan Antonio$7K
- Thomas SeymourConroe$6K
- Adolat MirzaevaHouston$5K
- Pedro YenMesquite$5K
- Clifford GarvinDenison$5K
- Namita TuliWharton$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.